Caricamento...
Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment
Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is a novel oral multikinase inhibitor that blocks the activity of several protein kinases. However, few guidelines exist for novel biomarkers to select patients who will likely benefit from regorafenib treatment. Metastatic colore...
Salvato in:
| Pubblicato in: | Ther Adv Med Oncol |
|---|---|
| Autori principali: | , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7649869/ https://ncbi.nlm.nih.gov/pubmed/33224274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920965842 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|